Skip to content
16 Nov 2020

Bone Therapeutics Uploaded a News Release
November 16, 2020

Bone Therapeutics announces completion of the acquisition of its cell therapy manufacturing subsidiary SCTS by Catalent

10 Nov 2020

Bone Therapeutics Uploaded a News Release
November 10, 2020

Bone Therapeutics and its collaborators Cerhum, 3D-Side, mSKIL and IREC awarded €3 million in funding under the framework of BioWin, the health cluster of Wallonia, to develop personalized, tissue engineered bone implants

  • Bone Therapeutics announces the start of a new research collaboration with Cerhum, 3D-Side, mSKIL, and IREC due to recently awarded funding of €3M
  • The funding was provided by Minister Willy Borsus, Vice-President of Wallonia, Belgium and Minister of Economy, Research and Innovation, Digital Technology, and Agriculture and Regional Planning
  • The collaborators with Bone Therapeutics have been established under the name “BioWin” and are made up of experts of and academic partners for the specialized industry dedicated to developing personalized, tissue engineered bone implants
  • The research will investigate and develop biologically active, patient-tailored, 3D printed, bioresorbable implants using Bone Therapeutics’ differentiated bone forming cells called ALLOB
  • The collaboration projects a duration of 28 months for this research under the name TrueBone3D and plans to use the bone implants to replace bone transplants harvested from patient’s own bones
  • TrueBone3D hopes to provide an alternative to bone autographs and to investigate the safety and effectiveness of bone implants as a treatment option for non-union fractures
1 Nov 2020

Bone Therapeutics Uploaded a Presentation
November 1, 2020

Bone Therapeutics Corporate Presentation

30 Oct 2020

Bone Therapeutics Uploaded a News Release
October 30, 2020

Bone Therapeutics Provides Third Quarter 2020 Business Update

  • Manufacturing collaboration with Catalent to streamline future ALLOB production
  • Catalent to acquire Bone Therapeutics’ cell therapy manufacturing facility for €12 million
  • Exclusive license agreement with Link Health and Pregene for €55 million total in upfront and milestone payments to develop and commercialize ALLOB in Greater China and adjacent Asian countries
  • Expansion of the product portfolio from orthopedics into inflammatory conditions
29 Oct 2020

Bone Therapeutics Uploaded a News Release
October 29, 2020

Bone Therapeutics and Catalent sign agreements to streamline production of the allogeneic cell therapy product, ALLOB

23 Oct 2020

Bone Therapeutics Uploaded a News Release
October 23, 2020

Information on the total number of voting rights and shares

23 Oct 2020

Bone Therapeutics Uploaded a News Release
October 23, 2020

Transparency notification received from S.R.I.W. SA and Sofipôle SA

20 Oct 2020

Bone Therapeutics Uploaded a News Release
October 20, 2020

Bone Therapeutics reaches 50% treated patients in ongoing JTA-004 Phase III pivotal knee osteoarthritis study

  • Recruitment on track to be completed before year-end
14 Oct 2020

Bone Therapeutics Uploaded a News Release
October 14, 2020

Bone Therapeutics’ allogeneic cell therapy product, ALLOB, shows 90% fusion rate at 24 months in Phase IIa study in lumbar spinal fusion

  • Bone Therapeutics announces positive 24-month follow-up results for the Phase IIa study with the allogeneic cell therapy product, ALLOB, in patients undergoing lumbar spinal fusion procedures.
  • The 24-month data show a high percentage of successful lumbar vertebrae fusion of 90%.
  • Patients also continue to experience important clinical improvements in function and pain, from as early as six months after treatment, up to the 24-month follow-up period.
14 Oct 2020

Bone Therapeutics Uploaded a News Release
October 14, 2020

Bone Therapeutics to present at 2020 Virtual Cell & Gene Meeting on the Mesa


  • Biotechnology / Drug Development

Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopedics and other diseases. The Company has a, diversified portfolio of cell and biologic therapies at different stages ranging from pre-clinical programs in immunomodulation to mid-to-late stage clinical development for orthopedic conditions, targeting markets with large unmet medical needs and limited innovation. Bone Therapeutics is developing an off-the-shelf next-generation improved viscosupplement, JTA-004, which is currently in phase III development for the treatment of pain in knee osteoarthritis. Consisting of a unique combination of plasma proteins, hyaluronic acid – a natural component of knee synovial fluid, and a fast-acting analgesic, JTA-004 intends to provide added lubrication and protection to the cartilage of the arthritic joint and to alleviate osteoarthritic pain and inflammation. Positive phase IIb efficacy results in patients with knee osteoarthritis showed a statistically significant improvement in pain relief compared to a leading viscosupplement. Bone Therapeutics’ core technology is based on its cutting-edge allogeneic cell therapy platform with differentiated bone marrow sourced Mesenchymal Stromal Cells (MSCs) which can be stored at the point of use in the hospital. Currently in pre-clinical development, BT-20, the most recent product candidate from this technology, targets inflammatory conditions, while the leading investigational medicinal product, ALLOB, represents a unique, proprietary approach to bone regeneration, which turns undifferentiated stromal cells from healthy donors into bone-forming cells. These cells are produced via the Bone Therapeutics’ scalable manufacturing process. Following the CTA approval by regulatory authorities in Europe, the Company is ready to start the phase IIb clinical trial with ALLOB in patients with difficult tibial fractures, using its optimized production process. ALLOB continues to be evaluated for other orthopedic indications including spinal fusion, osteotomy, maxillofacial and dental.

Show More + Show Less -


About Us | Please read our Privacy Policy, Cookie Policy, Disclaimer and Terms and Conditions. By accessing or using the Service you agree to be bound by these Terms. © 2023 Arrowhed Business and Investment Decisions, LLC.